Skip to content

Axsome Therapeutics AXSM Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$188.3M+32.3%-$183.17M+36.2%-$229.53M+26.2%-$246.9M+20.0%-$278.27M+6.1%
$470K-14.4%$503K-5.5%$518K-3.4%$529K-2.2%$549K+9.6%
$93.88M+6.3%$93.75M+10.0%$93.01M+13.2%$91.57M+21.6%$88.34M+26.4%
-$71.78M+39.3%-$94.45M+26.4%-$102M+23.1%-$120.63M+28.0%-$118.32M+38.6%
$263K-48.4%$480K+77.8%$439K+77.7%$471K-10.8%$510K-16.3%
-$263K+48.4%-$480K-77.8%-$439K-77.7%-$471K+10.8%-$510K+16.3%
$75.19M-14.8%$101.47M+75.4%$99.32M+128%$108.46M+133%$88.3M-68.3%
-$71.98M+39.4%-$94.87M+26.3%-$102.38M+22.9%-$121.1M+27.9%-$118.83M+38.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Axsome Therapeutics generate?
Axsome Therapeutics (AXSM) generated -$71.8M in operating cash flow over the trailing twelve months.
What is Axsome Therapeutics's free cash flow?
After $263.0K of capital expenditures, Axsome Therapeutics's free cash flow was -$72.0M over the trailing twelve months, up 39.4% year over year.
Where does Axsome Therapeutics's cash flow data come from?
Every line is extracted from Axsome Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.